

# Introduction

NEW YORK—Proven strategies for the effective management and prevention of complications due to hypertension remain of great interest to managed care professionals. This supplement, based on abstracts from the 21st Annual Scientific Meeting and Exposition of the American Society of Hypertension, held May 16-20, 2006, highlights presentations on:

- Phase 3 results of aliskiren, a novel, orally effective direct renin inhibitor for the treatment of hypertension
- Valsartan and the reduction of high-sensitivity C-reactive protein, a marker associated with a risk of hypertension
- Initial drug choice and its possible impact on comorbid disease
- The influence of economics and fixed-dose combinations on adherence and persistence.

---

## New Directions and Options for the Management of Hypertension

Highlights from the 21st Annual Scientific Meeting and Exposition  
of the American Society of Hypertension

---

### **Publishing Staff**

***Lara J. Reiman***

Projects Editor

***Kimberly A. Melofchik***

Associate Projects Editor

***William Doutré, PharmD***

Contributing Editor

***Wayne Kuznar***

Medical Writer

***Susan M. Carr***

Projects Production Director

***Charles Lebeda***

Senior Design/Production Manager

***Michael J. Molfetto***

Projects Design Director

***Scott Handschuch***

Project Publisher

***Barbara Marino***

Director, Quality Assurance

***Thomas Lorge***

Circulation Director

***Elizabeth Lang***

Director, Manufacturing and Production

***Linda N. Fox***

Vice President, Medical Group

***Will Passano***

President, Healthcare



---

### **Ascend Media Corporate Officers**

President & CEO  
***Cameron Bishop***

Executive Vice President & COO  
***Dan Altman***

Executive Vice President,  
Sales & Marketing  
***Ron Wall***

Senior Vice President & CFO  
***Mark Brockelman***

*Express Report* is published by  
Ascend Media Healthcare  
103 College Road East  
Princeton, NJ 08540  
(609) 524-9500  
©2006 Ascend Media  
All rights reserved.